IL103493A - Use of 2 - amino - 6 -) trifluoromethoxy (benzothiazole for the preparation of the drug for the treatment of neuro-motor diseases - Google Patents

Use of 2 - amino - 6 -) trifluoromethoxy (benzothiazole for the preparation of the drug for the treatment of neuro-motor diseases

Info

Publication number
IL103493A
IL103493A IL10349392A IL10349392A IL103493A IL 103493 A IL103493 A IL 103493A IL 10349392 A IL10349392 A IL 10349392A IL 10349392 A IL10349392 A IL 10349392A IL 103493 A IL103493 A IL 103493A
Authority
IL
Israel
Prior art keywords
amino
benzothiazole
treatment
trifluoromethoxy
preparing
Prior art date
Application number
IL10349392A
Other languages
English (en)
Hebrew (he)
Other versions
IL103493A0 (en
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9427427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL103493(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL103493A0 publication Critical patent/IL103493A0/xx
Publication of IL103493A publication Critical patent/IL103493A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Surgical Instruments (AREA)
  • Percussion Or Vibration Massage (AREA)
IL10349392A 1992-03-06 1992-10-21 Use of 2 - amino - 6 -) trifluoromethoxy (benzothiazole for the preparation of the drug for the treatment of neuro-motor diseases IL103493A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9202696A FR2688138B1 (fr) 1992-03-06 1992-03-06 Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Publications (2)

Publication Number Publication Date
IL103493A0 IL103493A0 (en) 1993-03-15
IL103493A true IL103493A (en) 1996-07-23

Family

ID=9427427

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10349392A IL103493A (en) 1992-03-06 1992-10-21 Use of 2 - amino - 6 -) trifluoromethoxy (benzothiazole for the preparation of the drug for the treatment of neuro-motor diseases

Country Status (22)

Country Link
US (1) US5527814A (ko)
EP (2) EP0558861A1 (ko)
JP (1) JP2713384B2 (ko)
KR (1) KR100190296B1 (ko)
AT (1) ATE149833T1 (ko)
AU (1) AU666150B2 (ko)
CA (1) CA2117466C (ko)
CZ (1) CZ281293B6 (ko)
DE (1) DE69218255T2 (ko)
DK (1) DK0627919T3 (ko)
ES (1) ES2098558T3 (ko)
FR (1) FR2688138B1 (ko)
GR (1) GR3022797T3 (ko)
HU (1) HU217130B (ko)
IL (1) IL103493A (ko)
MX (1) MX9206109A (ko)
NO (1) NO306534B1 (ko)
RU (1) RU2110260C1 (ko)
SK (1) SK279046B6 (ko)
UA (1) UA41879C2 (ko)
WO (1) WO1993017683A1 (ko)
ZA (1) ZA928213B (ko)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
NZ320355A (en) * 1995-10-26 2000-03-27 Sanofi Sa Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
CA2297943A1 (en) 1997-07-25 1999-02-04 Nippon Kayaku Kabushiki Kaisha Novel compound having effect of promoting neuron differentiation
US6417210B1 (en) 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
BR9906821A (pt) * 1998-01-09 2000-10-17 Mor Research Applic Ltd Composição farmacêutica e processo para melhorar a discinesia induzida por levodopa e discinesia tardia, e, uso de riluzol para a preparação de uma composição farmacêutica
FR2785808B1 (fr) * 1998-11-13 2002-12-06 Aventis Laboratoire Association riluzole et alpha-tocopherol
EP1552831B1 (en) * 1999-06-04 2009-01-07 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for treating multiple sclerosis
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
JP2001021609A (ja) * 1999-07-07 2001-01-26 Mitsubishi Electric Corp 半導体集積回路の検査方法
DE19940524C2 (de) * 1999-08-26 2003-06-18 Karl-Heinz Lenzkes Fahrzeugrad, insbesondere für Personenkraftfahrzeuge
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
US6964982B2 (en) * 2000-04-20 2005-11-15 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
US6933310B1 (en) 2000-10-24 2005-08-23 Mitsubishi Pharma Corporation Therapeutic agent for amyotrophic lateral sclerosis (ALS)
AU3932902A (en) * 2000-11-22 2002-06-03 Allergan Sales Inc A high-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels
US6479458B1 (en) 2001-11-08 2002-11-12 Allergan, Inc. Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
US7361478B2 (en) * 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
KR20040066890A (ko) * 2001-12-11 2004-07-27 유니버시티 오브 버지니아 페이턴트 파운데이션 근위축성 측삭 경화증 치료를 위한 프라미펙솔의 용도
US6927303B2 (en) * 2002-06-19 2005-08-09 Neurotech Co., Ltd. Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
AU2003290838A1 (en) * 2002-11-15 2004-06-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
MX2007014797A (es) * 2005-05-25 2008-02-15 Choongwae Pharma Corp Proceso de preparacion del compuesto tetrafluorobencilanilina y sus sales farmaceuticamente aprobadas.
US20070298129A1 (en) * 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
US20070049565A1 (en) * 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
CA2661448A1 (en) 2005-08-25 2007-03-01 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
JP5110536B2 (ja) 2006-07-19 2012-12-26 学校法人日本医科大学 筋萎縮性側索硬化症治療薬
US20100099700A1 (en) * 2006-09-20 2010-04-22 David Hung Hydrogenated pyrido (4,3-b) indoles for treating amyotrophic lateral sclerosis (als)
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (en) 2007-03-14 2010-05-19 Knopp Neurosciences Inc SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
KR100852962B1 (ko) * 2007-11-12 2008-08-20 주식회사 뉴로테크 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
BRPI0910338A2 (pt) * 2008-04-03 2020-08-18 F. Hoffmann-La Roche Ag uso de variantes peguiladas de igf-i para o tratamento de distúbios neuromusculares
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
EP2228055A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole liquid emulsions
JP2012530723A (ja) * 2009-06-19 2012-12-06 ノップ ニューロサイエンシーズ、インク． 筋萎縮性側索硬化症を治療するための組成物及び方法
JP2011121949A (ja) 2009-12-14 2011-06-23 Kyoto Univ 筋萎縮性側索硬化症の予防および治療用医薬組成物
EP2611437B1 (en) 2010-09-02 2017-03-29 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US10357497B2 (en) * 2012-06-23 2019-07-23 Biohaven Pharmaceutical Holding Company Limited Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
EP2882429B1 (en) 2012-08-07 2024-04-10 The General Hospital Corporation Potassium-channel openers for use in treating amyotrophic lateral sclerosis (ALS)
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
RS61539B1 (sr) 2013-07-12 2021-04-29 Knopp Biosciences Llc Lečenje povišenih nivoa eozinofila i/ili bazofila
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US20150210679A1 (en) * 2014-01-28 2015-07-30 Northwestern University Small molecule inhibitors of superoxide dismutase expression
WO2016114322A1 (ja) 2015-01-13 2016-07-21 国立大学法人京都大学 筋萎縮性側索硬化症の予防及び／又は治療剤
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
EP3631468A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
EP3630132A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US20210071258A1 (en) 2017-09-01 2021-03-11 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2020097155A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
PT3886894T (pt) 2018-11-30 2024-05-02 Juno Therapeutics Inc Métodos para dosagem e tratamento de malignidades de células b em terapia celular adotiva
SG11202105502RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for treatment using adoptive cell therapy
AU2020395318A1 (en) 2019-12-06 2022-06-09 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating B cell malignancies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
FR2619713B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
DE68903484T2 (de) * 1988-12-15 1993-03-18 Rhone Poulenc Sante 2-imino-6-polyfluoralkoxy-benzothiazol-derivate, verfahren zu deren herstellung und arzneimittel, die sie enthalten.
US5236940A (en) * 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
FR2649702B1 (fr) * 1989-07-13 1991-11-22 Rhone Poulenc Sante Derives d'alkylimino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2662160B1 (fr) * 1990-05-18 1992-07-24 Rhone Poulenc Sante Derives d'alkylthio-3 propyl-3 benzothiazoline leur preparation et les medicaments les contenant.
FR2663029B1 (fr) * 1990-06-07 1992-07-31 Rhone Poulenc Sante Derives de benzothiazole, leur preparation et les medicaments les contenant.

Also Published As

Publication number Publication date
CZ212094A3 (en) 1994-12-15
JPH07504655A (ja) 1995-05-25
GR3022797T3 (en) 1997-06-30
SK104794A3 (en) 1995-05-10
AU666150B2 (en) 1996-02-01
CZ281293B6 (cs) 1996-08-14
NO943256L (no) 1994-09-02
NO943256D0 (no) 1994-09-02
US5527814A (en) 1996-06-18
EP0627919A1 (fr) 1994-12-14
KR950700060A (ko) 1995-01-16
SK279046B6 (sk) 1998-06-03
UA41879C2 (uk) 2001-10-15
JP2713384B2 (ja) 1998-02-16
AU2948292A (en) 1993-10-05
CA2117466A1 (fr) 1993-09-16
KR100190296B1 (ko) 1999-06-01
WO1993017683A1 (fr) 1993-09-16
DK0627919T3 (da) 1997-05-12
ZA928213B (en) 1993-04-30
ATE149833T1 (de) 1997-03-15
CA2117466C (fr) 2000-01-25
RU2110260C1 (ru) 1998-05-10
EP0627919B1 (fr) 1997-03-12
HU217130B (hu) 1999-11-29
DE69218255T2 (de) 1997-09-11
HU9402558D0 (en) 1994-11-28
HUT70946A (en) 1995-11-28
NO306534B1 (no) 1999-11-22
ES2098558T3 (es) 1997-05-01
FR2688138A1 (fr) 1993-09-10
FR2688138B1 (fr) 1995-05-05
DE69218255D1 (de) 1997-04-17
RU94041223A (ru) 1996-10-20
EP0558861A1 (fr) 1993-09-08
IL103493A0 (en) 1993-03-15
MX9206109A (es) 1993-09-01

Similar Documents

Publication Publication Date Title
IL103493A (en) Use of 2 - amino - 6 -) trifluoromethoxy (benzothiazole for the preparation of the drug for the treatment of neuro-motor diseases
IL108284A (en) Pharmaceutical preparations containing rilosol for the treatment of Parkinson's disease and Parkinson's syndromes
PT687176E (pt) Aplicacao de riluzol no tratamento da neuro-sida
KR20070084123A (ko) 양극성 장애 및 관련 증상의 치료
JP3593357B2 (ja) 抗菌剤
JPH0196132A (ja) 精神分裂症を治療するためのある種の化合物の使用
JPWO2004017973A1 (ja) 統合失調症治療剤
DE69430047T2 (de) Pharmazeutische Zusammensetzungen die Isochinolinderivate enthalten
AU609564B2 (en) Anti-psychotic imidazobenzodiazepine
JP2003507352A (ja) 急なベンゾジアゼピン離脱処置のためのシアメマジンの使用
HU226067B1 (en) Pharmaceutical composition containing riluzole and alpha-tocopherol combination and its use
IL137608A (en) Use of 2-amino-6-trifluoromethoxy-benzothiazole in the preparation of drugs for the prevention or treatment of dysfunction of the serum
AU2001274195B2 (en) Use of riluzole or its salts for preventing and treating adrenoleukodystrophy
IL108283A (en) Use of rilozole for the preparation of a pharmaceutical preparation for increased rehabilitation after radiation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired